On December 11, 2025, Arbutus Biopharma's CEO, Lindsay Androski, will present details about the company's ongoing lawsuits against Moderna, Pfizer, and BioNTech concerning the use of its patented lipid nanoparticle technology in COVID-19 vaccines. This filing highlights significant litigation, which carries inherent risks and uncertainties.